Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on developing therapeutics for hematologic malignancies and solid tumors. The company entered the public markets in January 2021 through a de-SPAC merger with LifeSci Acquisition Corp, a blank-check vehicle sponsored by LifeSci Capital LLC that completed its initial public offering in 2020. A Form 8-K filed on January 16, 2025, under accession number 0001193125-25-007782, reflects Vincerx's continued obligations as a post-merger SEC reporting issuer operating in the oncology sector. For comprehensive data on Vincerx Pharma's SPAC transaction history, filing activity, and comparable deal analytics, sign up for full access at SpacDesk.